[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-352983-105":59,"doc-detail-352983-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","botulinum-neurotoxin-a-inhibits-tumor-growth-in-a-triple-negative-breast-cancer-preclinical-model","Botulinum Neurotoxin-A Inhibits Tumor Growth in a Triple-Negative Breast Cancer Preclinical Model","","Triple-negative breast cancer remains difficult to treat, motivating exploration of repurposed therapeutics. SV2A, a vesicular-release protein, is highlighted as a biomarker and molecular target in multiple cancers. This study evaluates botulinum neurotoxin type A (BoNT/A) for its ability to suppress tumor growth using both a 4T1 cell in vitro system and an orthotopic 4T1 mouse preclinical model. BoNT/A inhibited proliferation, reduced tumor burden, and lowered inflammation, linked to fewer blood neutrophils and monocytes.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/botulinum-neurotoxin-a-inhibits-tumor-growth-in-a-triple-negative-breast-cancer-preclinical-model/352983/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/botulinum-neurotoxin-a-inhibits-tumor-growth-in-a-triple-negative-breast-cancer-preclinical-model/352983.png","ImageObject",300,407,{"name":92,"@type":93},"Pentious","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-07","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main goal of the study?","Question",{"text":112,"@type":113},"To determine whether botulinum neurotoxin type A (BoNT/A) can inhibit tumor growth in a triple-negative breast cancer preclinical model.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was BoNT/A tested in the research?",{"text":117,"@type":113},"BoNT/A effects were evaluated in vitro using 4T1 cells and in vivo using orthotopically inoculated 4T1 cells in BALB/c mice.",{"name":119,"@type":110,"acceptedAnswer":120},"What outcomes did BoNT/A produce in the model?",{"text":121,"@type":113},"BoNT/A inhibited 4T1 cell proliferation, decreased tumor growth, and reduced inflammation, associated with fewer blood neutrophils and monocytes.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},352983,1790712121,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404730887,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Article  \nBotulinum Neurotoxin-A Inhibits Tumor Growth in a Triple-Negative Breast Cancer Preclinical Model  \nEvoli N. Lopez 1,2, Guadalupe Delgado-López 2, Paola Maycotte 3, Pablo Hernández-Jáuregui 2, Irma Herrera-Camacho 1, Nora Hilda Rosas-Murrieta 1, Eunice López-Muñoz 4,  \nClaudia Teresita Gutiérrez-Quiroz 5, Uriel Ramírez-Carrera 5, Cindy Bandala 6,  \nLourdes Millán-Pérez-Peña 1 and Maricruz Anaya-Ruiz 2, *  \n1 Laboratorio de Bioquímica y Biología Molecular, Centro de Química del Instituto de Ciencias (ICUAP), Benemérita Universidad Autónoma de Puebla, Puebla 72570, Mexico; [qfb.evolilopez@gmail.com](qfb.evolilopez@gmail.com) (E.N.L.); [irma.herrera@correo.buap.mx](irma.herrera@correo.buap.mx) (I.H.-C.); [nora.rosas@correo.buap.mx](nora.rosas@correo.buap.mx) (N.H.R.-M.); [lourdes.millan@correo.buap.mx](lourdes.millan@correo.buap.mx) (L.M.-P.-P.)  \n2 Laboratorio de Biología Celular del Cáncer, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla 74360, Mexico; [delgadoliy@yahoo.com.mx](delgadoliy@yahoo.com.mx) (G.D.-L.); [pablohja44@gmail.com](pablohja44@gmail.com) (P.H.-J.)  \n3 Laboratorio de Bioquímica Metabólica, Centro de Investigación Biomédica de Oriente, Instituto Mexicano del Seguro Social, Puebla 74360, Mexico; [bisbenzimida@gmail.com](bisbenzimida@gmail.com)  \n4 Unidad de Investigación Médica en Medicina Reproductiva UMAE Hospital de Gineco Obstetricia No. 4, Luis Castelazo Ayala, Instituto Mexicano del Seguro Social, Mexico City 01090, Mexico; [astridkaryme2001@yahoo.com.mx](astridkaryme2001@yahoo.com.mx)  \n5 Departamento de Anatomía Patológica, Centro Médico Nacional “General de División Manuel Ávila Camacho”, Hospital de Especialidades, Instituto Mexicano del Seguro Social, Puebla 72089, Mexico; [claudia.gutierrez@imss.gob.mx](claudia.gutierrez@imss.gob.mx) (C.T.G.-Q.); [hturc212@gmail.com](hturc212@gmail.com) (U.R.-C.)  \n6 Laboratorio de Neurociencia Traslacional en Enfermedades Crónicas y Emergentes, Escuela Superior de Medicina, Instituto Politécnico Nacional, Mexico City 11340, Mexico; [crodriguezba@ipn.mx](crodriguezba@ipn.mx)  \n* [Correspondence: maricruz.anaya@imss.gob.mx or manaya19@yahoo.com](Correspondence: maricruz.anaya@imss.gob.mx or manaya19@yahoo.com); Tel.: +52-2225109348  \nReceived: 12 November 2025  \nRevised: 23 December 2025  \nAccepted: 24 December 2025  \nPublished: 30 April 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \nAbstract  \nTriple-negative breast cancer (TNBC) continues to be a medical challenge requiring multiple treatment options. SV2A, a protein involved in vesicular release, has emerged as a promising biomarker for various cancers. Research shows that botulinum neurotoxin type A (BoNT/A), which binds to SV2A, the BoNT/A receptor, can inhibit the growth of prostate and breast cancer cells, suggesting its potential as an alternative treatment for breast cancer. The purpose of this study was to determine the potential of BoNT/A to inhibit tumor growth in a mouse preclinical model. BoNT/A was evaluated for its effects in an in vitro model employing 4T1 cells and in an in vivo model of orthotopically inoculated 4T1 cells in BALB/c mice. BoNT/A inhibited the proliferation of 4T1 cells, which express the SV2A protein; decreased tumor growth in the preclinical model; and decreased inflammation, associated with fewer blood neutrophils and monocytes, suggesting an immunomodulatory and anti-inflammatory effect. The effect of BoNT/A on the TNBC model supports its use as a repurposed drug for this type of aggressive cancer. Our results emphasize the significance of the SV2A receptor and its interaction with BoNT/A as promising therapeutic targets, particularly for TNBC.  \nKeywords: TNBC; botulinum neurotoxin A; SV2A; drug repurposing; preclinical model; immune system; 4T1  \nKey Contribution","cbCaipc50Joh4eis","https://ap.wps.com/l/cbCaipc50Joh4eis","pdf",2403884,18,"English","# Abstract\n## Keywords\n## Key Contribution\n## 1. Introduction","[{\"question\":\"What is the main goal of the study?\",\"answer\":\"To determine whether botulinum neurotoxin type A (BoNT/A) can inhibit tumor growth in a triple-negative breast cancer preclinical model.\"},{\"question\":\"How was BoNT/A tested in the research?\",\"answer\":\"BoNT/A effects were evaluated in vitro using 4T1 cells and in vivo using orthotopically inoculated 4T1 cells in BALB/c mice.\"},{\"question\":\"What outcomes did BoNT/A produce in the model?\",\"answer\":\"BoNT/A inhibited 4T1 cell proliferation, decreased tumor growth, and reduced inflammation, associated with fewer blood neutrophils and monocytes.\"}]","Botulinum Neurotoxin-A Inhibits Tumor Growth in a Triple-Negative Breast Cancer Preclinical Model | PDF",1790102414,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e7b281f8a574fa1b07f502b288ad21e.webp",983,1390,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c4c54d18b61f558044acce1d21c60efe.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b39687148ee4f2038acba03146863f7c.webp",981,1387,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fffd01fa72c8a804301bcf038233a7b5.webp",980,1385]